High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy
Authors:
Open Access
Abstract
Diffuse large B-cell lymphoma (DLBCL) is characterized by high molecular and clinical heterogeneity. Autophagy, a lysosome-driven catabolic process devoted to macromolecular turnover, is fundamental in maintaining normal hematopoietic stem cells and progenitors homeostasis, and its dysregulation plays a critical role in the initiation and progression of hematological malignancies. One main regulator of autophagy is BECLIN-1, which may interact alternatively with either BCL-2, thus allowing apoptosis, or PI3KC3, thus promoting autophagy. The altered expression of BCL2 and BECN1 correlates with lymphoma outcomes, but whether this is associated with dysregulated cross-talk between autophagy and apoptosis remains to be elucidated. Analysis of the TCGA database revealed that BCL2 and BECN1 mRNA expression were inversely correlated in DLBCL patients. In representative DLBCL cell lines exposed to doxorubicin, the cells highly expressing BCL-2 were resistant, while the ones highly expressing BECLIN-1 were sensitive, and this correlated with low and high autophagy flux, respectively. Venetoclax targeting of BCL-2 increased while the spautin-1-mediated inhibition of BECLIN-1-dependent autophagy reversed doxorubicin sensitivity in the former and in the latter, respectively. By interrogating the TCGA DLBCL dataset, we found that BCL2 and BECN1 acted as negative and positive prognostic markers for DLBCL, respectively. The differentially expressed gene analysis in the respective cohorts revealed that BCL2 positively correlated with oncogenic pathways (e.g., glucose transport, HIF1A signaling, JAK-STAT signaling, PI3K-AKT-mTOR pathway) and negatively correlated with autophagy-related transcripts, while BECN1 showed the opposite trend. Notably, patients with high BECN1 expression displayed longer survival. Our data reveal, for the first time, that the modulation of BECLIN-1-dependent autophagy influences the prognosis of DLBCL patients and provide a mechanistic explanation supporting the therapeutic use of drugs that, by stimulating autophagy, can sensitize lymphoma cells to chemotherapy.Keywords
Funding Information
- Fondazione Italiana per la Ricerca sul Cancro (21198, 2015ZMRFEA)
- Ministero dell’Istruzione, dell’Università e della Ricerca (21198, 2015ZMRFEA)
- the AGING Project—Department of Excellence—DIMET, Università del Piemonte Orientale, Novara, Italy (21198, 2015ZMRFEA)
- AIL Novara Onlus, Novara, Italy (21198, 2015ZMRFEA)
This publication has 49 references indexed in Scilit:
- Autophagy in blood cancers: biological role and therapeutic implicationsHaematologica, 2013
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingProceedings of the National Academy of Sciences, 2012
- BCL2 mutations in diffuse large B-cell lymphomaLeukemia, 2011
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomasBritish Journal of Haematology, 2011
- The Beclin 1 network regulates autophagy and apoptosisCell Death & Differentiation, 2011
- Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomasLaboratory Investigation, 2010
- BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphomaProceedings of the National Academy of Sciences, 2009
- The autophagy effector Beclin 1: a novel BH3-only proteinOncogene, 2008
- Bcl-2 Inhibition of Autophagy: A New Route to Cancer?Cancer Research, 2006